<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00968695</url>
  </required_header>
  <id_info>
    <org_study_id>IG0802</org_study_id>
    <nct_id>NCT00968695</nct_id>
  </id_info>
  <brief_title>Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites.</brief_title>
  <official_title>Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joan Albert Arnaiz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Grifols, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacodynamic study of pathophysiological nature to assess the effects of prolonged
      administration of human albumin in the cardiocirculatory and renal function and hepatic
      hemodynamics in patients with advanced cirrhosis and ascites.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To asses plasma renin activity and plasma concentration of noradrenaline</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular filtration</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Portal hypertension</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Function</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Ascites</condition>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>The pattern of administration of 20% human albumin is 1'5g/kg every week to infuse in 6 hours with a minimum of 90 g up to 150 g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.</description>
    <arm_group_label>Albumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age above 18 years and less than 80 years.

          -  Diagnosis of liver cirrhosis by biopsy or by clinical, laboratory, or ultrasound.

          -  Daily requirement of diuretics at least 200mg of spironolactone or 100mg of
             spironolactone and 40 mg of furosemide

          -  Renal dysfunction defined by a plasma concentration of serum creatinine ≥ 1.2 mg / dl,
             BUN ≥ 25 mg / dl or a serum sodium concentration ≤ 130 mEq / L.

        Exclusion Criteria:

          -  Refractory Ascites (paracentesis requirements over 1 month.

          -  Neoplastic disease including liver cancer if it exceeds the Milan criteria (one
             nodule&gt; 5 cm or three nodules&gt; 3 cm).

          -  History of transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt

          -  Gastrointestinal bleeding or bacterial infection documented in the past 15 days.

          -  Heart failure or structural heart disease.

          -  Organic renal insufficiency(proteinuria, hematuria and / or ultrasound data
             nephropathy).

          -  Moderate or severe lung chronic disease.

          -  Transplant.

          -  Infection with human immunodeficiency virus.

          -  Active addiction to drugs.

          -  Mental state that prevents the patient understand the nature, extent and consequences
             of the study, except for hepatic encephalopathy.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Arroyo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2009</study_first_submitted>
  <study_first_submitted_qc>August 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2009</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Grifols, S.A.</investigator_affiliation>
    <investigator_full_name>Joan Albert Arnaiz</investigator_full_name>
    <investigator_title>Project manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

